Last reviewed · How we verify

Regimen:TDF+3TC+EFV — Competitive Intelligence Brief

Regimen:TDF+3TC+EFV (Regimen:TDF+3TC+EFV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Regimen:TDF+3TC+EFV (Regimen:TDF+3TC+EFV) — National Center for AIDS/STD Control and Prevention, China CDC. This combination regimen inhibits HIV reverse transcriptase and integrase through three antiretroviral agents, preventing viral replication and reducing viral load.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Regimen:TDF+3TC+EFV TARGET Regimen:TDF+3TC+EFV National Center for AIDS/STD Control and Prevention, China CDC marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
Truvada Pill Truvada Pill University of North Carolina, Chapel Hill marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Dolutegravir/Lamivudine as a single pill Dolutegravir/Lamivudine as a single pill Fundacion SEIMC-GESIDA marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
Lamivudine/Zidovudine Lamivudine/Zidovudine Bristol-Myers Squibb marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
tenofovir disproxil fumarate/emtricitabine tenofovir disproxil fumarate/emtricitabine Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections marketed Nucleoside/nucleotide reverse transcriptase inhibitor combination HIV reverse transcriptase
nucleoside reverse transcriptase inhibitors nucleoside reverse transcriptase inhibitors French National Agency for Research on AIDS and Viral Hepatitis marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Lamiduvine (Epivir) Lamiduvine (Epivir) Catholic University of the Sacred Heart marketed Nucleoside Reverse Transcriptase Inhibitor (NRTI) HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
  3. Hospital Clinic of Barcelona · 1 drug in this class
  4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
  5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
  6. Peking Union Medical College Hospital · 1 drug in this class
  7. Sheba Medical Center · 1 drug in this class
  8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
  9. University of KwaZulu · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Regimen:TDF+3TC+EFV — Competitive Intelligence Brief. https://druglandscape.com/ci/regimen-tdf-3tc-efv. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: